This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Corneal Disorders  • Drug Therapy  • Alert me on articles by topic

Valerie P. J. Saw, FRANZCO; Neil Cornelius, FCOphth(SA); Alan D. Salama, PhD, FRCP; Charles Pusey, PhD, FRCP; Susan L. Lightman, PhD, FRCOphth

Arch Ophthalmol. 2008;126(5):734.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Mooren ulceration is an uncommon corneal autoimmune disease that can lead to blindness. We describe a patient with aggressive disease in whom inflammatory control was only achieved after infusion of a tumor necrosis factor antagonist, infliximab.

Report of a Case

A 37-year-old Nigerian man with a 14-year history of bilateral Mooren ulceration had a right corneal perforation and a desmetocele in his severely damaged left eye (Figure, A and B). Snellen visual acuity was 6/60 OD, improving to 6/36 OD with pinhole, and hand movements OS. Systemic cyclosporine at a dosage of 5 mg/kg/d and prednisolone tapering from 1 mg/kg/d and ceasing after 8 weeks were given, with 2% cyclosporine eyedrops and ofloxacin eyedrops both 3 times daily to the right eye. The right corneal perforation healed with glue and . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION